Form 4 for UTHR UNITED THERAPEUTICS Corp
Accepted 2026-04-02 16:34:01 ET · period of report 2026-03-31 · accession 0001106578-26-000024 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-04-02 16:34 | 2026-03-31 | UTHR | ROTHBLATT MARTINE A | COB, CEO, Dir | M - OptEx | $146.03 | +9,500 | 50.0K | +23% | +$1.39M |
| DMT | 2026-04-02 16:34 | 2026-03-31 | UTHR | ROTHBLATT MARTINE A | COB, CEO, Dir | S - Sale+OE | $585.76 | -9,500 | 40.5K | -19% | -$5.56M |
| DT | 2026-04-02 16:34 | 2026-03-31 | UTHR | ROTHBLATT MARTINE A | COB, CEO, Dir | M - OptEx | $0.00 | -9,500 | 31.0K | -23% | $0 |
| DMTI | 2026-04-02 16:34 | 2026-04-01 | UTHR | ROTHBLATT MARTINE A | COB, CEO, Dir | G - Gift | $0.00 | 0 | 500.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-31 | M | A | 9,500 | $146.03 | 50,013 | D | — | — | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. |
| 2 | Common | Common Stock | 2026-03-31 | S | D | 80 | $574.55 | 49,933 | D | — | — | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F2) This transaction was executed in multiple trades at prices ranging from $574.55 to $574.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 3 | Common | Common Stock | 2026-03-31 | S | D | 160 | $577.54 | 49,773 | D | — | — | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F3) This transaction was executed in multiple trades at prices ranging from $577.39 to $577.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 4 | Common | Common Stock | 2026-03-31 | S | D | 240 | $580.08 | 49,533 | D | — | — | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F4) This transaction was executed in multiple trades at prices ranging from $579.43 to $580.32. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 5 | Common | Common Stock | 2026-03-31 | S | D | 503 | $581.10 | 49,030 | D | — | — | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F5) This transaction was executed in multiple trades at prices ranging from $580.52 to $581.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 6 | Common | Common Stock | 2026-03-31 | S | D | 805 | $582.19 | 48,225 | D | — | — | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F6) This transaction was executed in multiple trades at prices ranging from $581.56 to $582.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 7 | Common | Common Stock | 2026-03-31 | S | D | 1,391 | $583.08 | 46,834 | D | — | — | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F7) This transaction was executed in multiple trades at prices ranging from $582.58 to $583.57. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 8 | Common | Common Stock | 2026-03-31 | S | D | 980 | $584.04 | 45,854 | D | — | — | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F8) This transaction was executed in multiple trades at prices ranging from $583.58 to $584.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 9 | Common | Common Stock | 2026-03-31 | S | D | 1,161 | $585.00 | 44,693 | D | — | — | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F9) This transaction was executed in multiple trades at prices ranging from $584.58 to $585.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 10 | Common | Common Stock | 2026-03-31 | S | D | 886 | $586.14 | 43,807 | D | — | — | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F10) This transaction was executed in multiple trades at prices ranging from $585.73 to $586.68. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 11 | Common | Common Stock | 2026-03-31 | S | D | 467 | $587.37 | 43,340 | D | — | — | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F11) This transaction was executed in multiple trades at prices ranging from $586.875 to $587.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 12 | Common | Common Stock | 2026-03-31 | S | D | 567 | $588.38 | 42,773 | D | — | — | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F12) This transaction was executed in multiple trades at prices ranging from $587.88 to $588.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 13 | Common | Common Stock | 2026-03-31 | S | D | 600 | $589.40 | 42,173 | D | — | — | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F13) This transaction was executed in multiple trades at prices ranging from $588.89 to $589.88. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 14 | Common | Common Stock | 2026-03-31 | S | D | 760 | $590.36 | 41,413 | D | — | — | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F14) This transaction was executed in multiple trades at prices ranging from $589.95 to $590.90. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 15 | Common | Common Stock | 2026-03-31 | S | D | 700 | $593.13 | 40,713 | D | — | — | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F15) This transaction was executed in multiple trades at prices ranging from $592.63 to $593.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 16 | Common | Common Stock | 2026-03-31 | S | D | 200 | $594.11 | 40,513 | D | — | — | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F16) This transaction was executed in multiple trades at prices ranging from $594.00 to $594.18. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 17 | Derivative | Stock Option | 2026-03-31 | M | D | 9,500 | $0.00 | 31,000 | D | $146.03 · 2020-03-15 to 2027-03-15 | 9,500 Common Stock | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. |
| 18 | Derivative | Stock Option | 2026-04-01 | G | D | 349,192 | $0.00 | 349,192 | I By Trust | $135.42 · 2023-03-15 to 2027-03-15 | 349,192 Common Stock | (F20) This stock option was gifted from a trust beneficially owned by the Reporting Person to a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries. The gift was made pursuant to an agreement entered into on November 21, 2025 which provided that the number of stock options to be gifted would be based on set formula using a valuation to be conducted on April 1, 2026. The actual number of stock options to be gifted was determined on April 1, 2026 and the gift occurred on the same date. No funds were exchanged, and no sale of shares occurred in the gift. (F20) This stock option was gifted from a trust beneficially owned by the Reporting Person to a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries. The gift was made pursuant to an agreement entered into on November 21, 2025 which provided that the number of stock options to be gifted would be based on set formula using a valuation to be conducted on April 1, 2026. The actual number of stock options to be gifted was determined on April 1, 2026 and the gift occurred on the same date. No funds were exchanged, and no sale of shares occurred in the gift. |
| 19 | Derivative | Stock Options | 2026-04-01 | G | A | 349,192 | $0.00 | 349,192 | I By Trust | $135.42 · 2023-03-15 to 2027-03-15 | 349,192 Common Stock | (F20) This stock option was gifted from a trust beneficially owned by the Reporting Person to a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries. The gift was made pursuant to an agreement entered into on November 21, 2025 which provided that the number of stock options to be gifted would be based on set formula using a valuation to be conducted on April 1, 2026. The actual number of stock options to be gifted was determined on April 1, 2026 and the gift occurred on the same date. No funds were exchanged, and no sale of shares occurred in the gift. (F20) This stock option was gifted from a trust beneficially owned by the Reporting Person to a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries. The gift was made pursuant to an agreement entered into on November 21, 2025 which provided that the number of stock options to be gifted would be based on set formula using a valuation to be conducted on April 1, 2026. The actual number of stock options to be gifted was determined on April 1, 2026 and the gift occurred on the same date. No funds were exchanged, and no sale of shares occurred in the gift. |
| 20 | Derivative | Stock Options | 2026-04-01 | G | D | 500,000 | $0.00 | 0 | I By Trusts | $117.76 · — to 2027-03-15 | 500,000 Common Stock | (F20) This stock option was gifted from a trust beneficially owned by the Reporting Person to a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries. The gift was made pursuant to an agreement entered into on November 21, 2025 which provided that the number of stock options to be gifted would be based on set formula using a valuation to be conducted on April 1, 2026. The actual number of stock options to be gifted was determined on April 1, 2026 and the gift occurred on the same date. No funds were exchanged, and no sale of shares occurred in the gift. (F21) This stock option become exercisable in three equal annual installments beginning on the second anniversary of the grant date. The stock option was granted on March 15, 2019. (F20) This stock option was gifted from a trust beneficially owned by the Reporting Person to a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries. The gift was made pursuant to an agreement entered into on November 21, 2025 which provided that the number of stock options to be gifted would be based on set formula using a valuation to be conducted on April 1, 2026. The actual number of stock options to be gifted was determined on April 1, 2026 and the gift occurred on the same date. No funds were exchanged, and no sale of shares occurred in the gift. |
| 21 | Derivative | Stock Options | 2026-04-01 | G | A | 500,000 | $0.00 | 500,000 | I By Trusts | $117.76 · — to 2027-03-15 | 500,000 Common Stock | (F20) This stock option was gifted from a trust beneficially owned by the Reporting Person to a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries. The gift was made pursuant to an agreement entered into on November 21, 2025 which provided that the number of stock options to be gifted would be based on set formula using a valuation to be conducted on April 1, 2026. The actual number of stock options to be gifted was determined on April 1, 2026 and the gift occurred on the same date. No funds were exchanged, and no sale of shares occurred in the gift. (F21) This stock option become exercisable in three equal annual installments beginning on the second anniversary of the grant date. The stock option was granted on March 15, 2019. (F20) This stock option was gifted from a trust beneficially owned by the Reporting Person to a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries. The gift was made pursuant to an agreement entered into on November 21, 2025 which provided that the number of stock options to be gifted would be based on set formula using a valuation to be conducted on April 1, 2026. The actual number of stock options to be gifted was determined on April 1, 2026 and the gift occurred on the same date. No funds were exchanged, and no sale of shares occurred in the gift. |